Synonym
MF-438; MF 438; MF438.
IUPAC/Chemical Name
2-methyl-5-(6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)pyridazin-3-yl)-1,3,4-thiadiazole
InChi Key
NVUJDKDVOZVALT-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18F3N5OS/c1-12-23-26-18(29-12)15-6-7-17(25-24-15)27-10-8-13(9-11-27)28-16-5-3-2-4-14(16)19(20,21)22/h2-7,13H,8-11H2,1H3
SMILES Code
FC(C1=CC=CC=C1OC2CCN(C3=NN=C(C4=NN=C(C)S4)C=C3)CC2)(F)F
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1.
In vitro activity:
A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor.
Reference: Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. https://pubmed.ncbi.nlm.nih.gov/20004097/
In vivo activity:
Female Wistar rats with an average weight of 200±20 g were subjected to this study. After mating, pregnant rats were divided into three groups and gavaged with the vehicle, MF 438 or MF-438 plus oleate from day 3 of pregnancy for five days. elatively, deficient morphological indices and hepatic maturation markers were observed in fetus livers of the inhibitor-treated group. In comparison to the other two groups, total hepatic protein and glycogen content were increased with treatment of MF-438 plus oleate. Hepatocyte nuclear factor 1α, alpha fetoprotein, albumin, and cytochrome P450 gene expression were also significantly increased in the group treated with both MF-438 and oleate.
Reference: Iran J Basic Med Sci. 2019 Sep;22(9):1010-1015. https://pubmed.ncbi.nlm.nih.gov/31807244/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Ethanol |
8.0 |
18.98 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
421.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Luo H, Wang X, Song S, Wang Y, Dan Q, Ge H. Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma. Oncoimmunology. 2022 Jul 15;11(1):2101769. doi: 10.1080/2162402X.2022.2101769. PMID: 35859734; PMCID: PMC9291654.
2. Léger S, Black WC, Deschenes D, Dolman S, Falgueyret JP, Gagnon M, Guiral S, Huang Z, Guay J, Leblanc Y, Li CS, Massé F, Oballa R, Zhang L. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. doi: 10.1016/j.bmcl.2009.11.111. Epub 2009 Nov 26. PMID: 20004097.
3. Mohammadzadeh F, Alihemmati A, Pirpour Tazehkand A, Darabi M, Mehdizadeh A. Early oleate deficiency leads to severe defects in fetal rat liver development. Iran J Basic Med Sci. 2019 Sep;22(9):1010-1015. doi: 10.22038/ijbms.2019.35084.8345. PMID: 31807244; PMCID: PMC6880538.
In vitro protocol:
1. Luo H, Wang X, Song S, Wang Y, Dan Q, Ge H. Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma. Oncoimmunology. 2022 Jul 15;11(1):2101769. doi: 10.1080/2162402X.2022.2101769. PMID: 35859734; PMCID: PMC9291654.
2. Léger S, Black WC, Deschenes D, Dolman S, Falgueyret JP, Gagnon M, Guiral S, Huang Z, Guay J, Leblanc Y, Li CS, Massé F, Oballa R, Zhang L. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. doi: 10.1016/j.bmcl.2009.11.111. Epub 2009 Nov 26. PMID: 20004097.
In vivo protocol:
1. Mohammadzadeh F, Alihemmati A, Pirpour Tazehkand A, Darabi M, Mehdizadeh A. Early oleate deficiency leads to severe defects in fetal rat liver development. Iran J Basic Med Sci. 2019 Sep;22(9):1010-1015. doi: 10.22038/ijbms.2019.35084.8345. PMID: 31807244; PMCID: PMC6880538.
1: Pisanu ME, Noto A, De Vitis C, Morrone S, Scognamiglio G, Botti G, Venuta F,
Diso D, Jakopin Z, Padula F, Ricci A, Mariotta S, Giovagnoli MR, Giarnieri E,
Amelio I, Agostini M, Melino G, Ciliberto G, Mancini R. Blockade of
Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer
stem cells. Cancer Lett. 2017 Oct 10;406:93-104. doi:
10.1016/j.canlet.2017.07.027. Epub 2017 Aug 7. PubMed PMID: 28797843.
2: Léger S, Black WC, Deschenes D, Dolman S, Falgueyret JP, Gagnon M, Guiral S,
Huang Z, Guay J, Leblanc Y, Li CS, Massé F, Oballa R, Zhang L. Synthesis and
biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. doi: 10.1016/j.bmcl.2009.11.111.
Epub 2009 Nov 26. PubMed PMID: 20004097.
